BioDuro and Cenra Form Strategic Joint Venture to Strengthen Global API Manufacturing Network
Key Insights
BioDuro (search), a US-based CRDMO, has established a joint venture with Taiwan's Cenra API Solutions (search) to expand commercial-scale API manufacturing capacity at Cenra's Taipei facility.
The partnership integrates BioDuro (search)'s early-stage drug development expertise with Cenra's six decades of GMP manufacturing experience to provide end-to-end API solutions.
The Taipei campus features 10 GMP production lines with over 350,000 liters of reactor volume, capable of producing up to 200 metric tons of APIs annually.
US-based BioDuro (search), a globally trusted Contract Research, Development, and Manufacturing Organization (CRDMO), has established a strategic joint venture with Cenra API Solutions (search) to significantly expand commercial-scale active pharmaceutical ingredient (API) manufacturing capacity. The partnership with Cenra, also known as Chunghwa Chemical Synthesis & Biotech (search) (CCSB (search)), leverages the Taiwanese company's nearly six decades of pharmaceutical manufacturing expertise to strengthen BioDuro's global network.
Strategic Integration of Complementary Capabilities
The joint venture combines BioDuro (search)'s strengths in early-stage drug development with Cenra's expertise in commercial-scale GMP API manufacturing. This integration enables the partnership to provide global clients with comprehensive API solutions spanning from early development through commercial-scale production.
"By combining BioDuro (search)'s integrated CMC expertise with Cenra's nearly six decades of GMP manufacturing excellence and enviable international regulatory history, our joint venture strengthens both companies' global supply chain resilience and minimizes the risks of technology-transfers," said Armin Spura, Ph.D., CEO of BioDuro.
Substantial Manufacturing Infrastructure
The Taipei campus houses 10 GMP API production lines with a total reactor volume exceeding 350,000 liters, supporting annual API output of up to 200 metric tons. The facility has successfully undergone inspections by several major international regulatory agencies, including the US FDA (search), EMA, Japan's PMDA, and Taiwan's TFDA (search).
This regulatory approval across multiple jurisdictions provides clients with enhanced flexibility in global drug development and commercialization strategies. The facility's established compliance record reduces regulatory risks for pharmaceutical companies seeking to diversify their API supply chains.
Enhanced Service Portfolio
The collaboration allows BioDuro (search) to offer customers integrated services encompassing discovery chemistry, process R&D, regulatory starting materials, advanced intermediates, and clinical- to commercial-scale API production both inside and outside mainland China. This comprehensive approach aims to accelerate the advancement of innovative therapies to market for patients worldwide.
"BioDuro (search) serves more than 1,500 global customers annually with industry-leading R&D and manufacturing capabilities," added Wayne Hsiao, President of Cenra API Solutions (search). "We are excited to join forces to deliver highly integrated solutions and greater value to customers around the world."
Company Backgrounds
BioDuro (search), an Advent (search) portfolio company, operates as a CRDMO with a 30-year proven track record. Headquartered in Irvine, California, the company employs more than 2,000 scientists with expertise in small- and large-molecule discovery, development, and manufacturing.
Founded in 1964, Chunghwa Chemical Synthesis & Biotech (search) Co., Ltd. operates as Cenra API Solutions (search), part of the CENRA Group (search). Cenra was the first API manufacturer in Taiwan to receive US FDA (search) approval and focuses on developing and manufacturing high-value and complex APIs. The company leverages advanced biotechnology, fermentation, and chemical synthesis platforms to serve customers in over 50 countries worldwide.